文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

非典型抗精神病药治疗痴呆行为和心理症状的疗效与安全性比较:一项网络Meta分析

Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia: A Network Meta-analysis.
PubMed 文献 · JAMA Netw Open · 2019-03-01
一句话结论网络Meta分析(17项RCT、5373例)显示非典型抗精神病药疗效与安全性存在权衡,无单一最优药物,作者建议个体化评估风险获益。

该网络Meta分析检索PubMed/MEDLINE、Embase、PsychINFO和Cochrane Library至2018年5月31日,纳入17项随机临床试验(5373例)比较非典型抗精神病药或安慰剂治疗痴呆行为和心理症状(BPSD)。与安慰剂相比,阿立哌唑改善NPI(SMD -0.17)、BPRS(SMD -0.20)和CMAI(SMD -0.30),喹硫平改善BPRS(SMD -0.24),利培酮改善CMAI(SMD -0.26);利培酮(OR 3.85)和奥氮平(OR 4.28)增加脑血管不良事件风险。各非典型抗精神病药之间在疗效、死亡和脑血管不良事件方面无显著差异。作者结论认为不存在单一最有效且安全的治疗选择,处方时应个体化权衡安全性风险与预期获益。

要点

  • 与安慰剂相比,阿立哌唑改善NPI(SMD -0.17;95%CI -0.31至-0.02)、BPRS(SMD -0.20;95%CI -0.35至-0.05)和CMAI(SMD -0.30;95%CI -0.55至-0.05)。
  • 与安慰剂相比,喹硫平改善BPRS(SMD -0.24;95%CI -0.46至-0.01),利培酮改善CMAI(SMD -0.26;95%CI -0.37至-0.15)。
  • 与安慰剂相比,利培酮(OR 3.85;95%CI 1.55-9.55)和奥氮平(OR 4.28;95%CI 1.26-14.56)与脑血管不良事件风险增加相关。
  • 各非典型抗精神病药之间在疗效、死亡或脑血管不良事件方面差异无统计学意义。
  • SUCRA提示阿立哌唑可能最有效且安全、奥氮平总体获益最少,但点估计(OR和SMD)显示无统计学显著差异,应谨慎解读。

适用人群与场景

  • 随机临床试验中比较任何非典型抗精神病药与另一种非典型抗精神病药或安慰剂治疗的痴呆行为和心理症状(BPSD)患者,共17项研究、5373例,平均(SD)年龄80.8(3.1)岁,女性3748例(69.8%)。

研究设计与关键结果

  • 研究设计:网络Meta分析,纳入17项随机临床试验(5373例),比较非典型抗精神病药之间或与安慰剂;主要疗效终点为神经精神问卷(NPI),次要疗效终点为简明精神病评定量表(BPRS)和Cohen-Mansfield激越问卷(CMAI);主要安全终点为死亡和脑血管不良事件(CVAEs)。
  • 与安慰剂相比,阿立哌唑改善NPI(SMD -0.17;95%CI -0.31至-0.02)、BPRS(SMD -0.20;95%CI -0.35至-0.05)和CMAI(SMD -0.30;95%CI -0.55至-0.05)。
  • 与安慰剂相比,喹硫平改善BPRS(SMD -0.24;95%CI -0.46至-0.01),利培酮改善CMAI(SMD -0.26;95%CI -0.37至-0.15)。
  • 各非典型抗精神病药之间在疗效、死亡或CVAE方面差异无统计学意义。
  • 与安慰剂相比,利培酮(OR 3.85;95%CI 1.55-9.55)和奥氮平(OR 4.28;95%CI 1.26-14.56)与CVAE风险增加相关。
  • SUCRA估计的相对排名提示阿立哌唑可能为最有效且安全的非典型抗精神病药、奥氮平总体获益最少;但这些结果应谨慎解读,点估计(OR和SMD)显示无统计学显著差异。

证据类型、等级与局限

  • 证据类型:网络Meta分析,纳入17项随机临床试验(5373例),检索PubMed/MEDLINE、Embase、PsychINFO和Cochrane Library至2018年5月31日,采用随机效应模型,效应量为SMD(连续变量)和OR(二分类变量)及95%CI。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,临床医生为痴呆患者处方非典型抗精神病药时,应个体化评估安全性风险与预期获益。
  • 作者结论支持非典型抗精神病药治疗BPSD存在疗效与安全性的权衡,并确认不存在单一最有效且安全的治疗选择。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Atypical antipsychotics offer modest effectiveness compared with placebo but with serious safety risks, including a boxed warning for the risk of death in the treatment of behavioral and psychological symptoms of dementia (BPSD). Their comparative effectiveness and safety are not fully known.

OBJECTIVE: To assess the relative benefits and safety of atypical antipsychotics in the treatment of BPSD shown in randomized clinical trials using network meta-analysis.

DATA SOURCES: PubMed/MEDLINE, Embase, PsychINFO, and Cochrane Library were searched from their inception until May 31, 2018. Key terms included dementia and atypical antipsychotics.

STUDY SELECTION: Randomized clinical trials comparing any atypical antipsychotic with another atypical antipsychotic or with placebo were included in the analysis.

DATA EXTRACTION AND SYNTHESIS: Two independent reviewers used a standardized data extraction and quality assessment form. Random-effects network meta-analyses were performed. Effect sizes were reported as standardized mean differences (SMDs) for continuous outcomes and odds ratios (ORs) for dichotomous outcomes with 95% CIs. In addition to ORs, the surface under the cumulative ranking curve (SUCRA) was ascertained, which represents the percentage of the effectiveness or safety for each treatment compared with a hypothetical treatment that would be ranked first without uncertainty.

MAIN OUTCOMES AND MEASURES: The primary effectiveness outcome assessed was the Neuropsychiatric Inventory (NPI); secondary effectiveness outcomes were the Brief Psychiatric Rating Scale (BPRS) and Cohen-Mansfield Agitation Inventory (CMAI). The primary safety outcomes were death and cerebrovascular adverse events (CVAEs). Secondary safety outcomes were extrapyramidal signs/symptoms; somnolence/sedation; falls, fracture, or injury; and urinary tract infection/incontinence.

RESULTS: Seventeen studies (5373 patients) were included. The mean (SD) age of all participants was 80.8 (3.1) years, and most were women (3748 [69.8%]). Compared with placebo, aripiprazole was associated with improvement in outcomes on the NPI (SMD, -0.17; 95% CI, -0.31 to -0.02), BPRS (SMD, -0.20; 95% CI, -0.35 to -0.05), and CMAI (SMD, -0.30; 95% CI, -0.55 to -0.05); quetiapine was associated with improvement in outcomes on the BPRS (SMD, -0.24; 95% CI, -0.46 to -0.01), and risperidone was associated with improvement in outcomes on the CMAI (SMD, -0.26; 95% CI, -0.37 to -0.15). Differences between atypical antipsychotics were not significant for effectiveness, death, or CVAE. Compared with placebo, risperidone (OR, 3.85; 95% CI, 1.55-9.55) and olanzapine (OR, 4.28; 95% CI, 1.26-14.56) were associated with increased risk of CVAEs. The SUCRA estimated relative ranking of treatments suggested that aripiprazole might be the most effective and safe atypical antipsychotic and that olanzapine provides the least benefit overall; however, these results should be interpreted with caution where point estimates (OR and SMD) show that there is no statistically significant difference.

CONCLUSIONS AND RELEVANCE: This network meta-analysis supports the existence of a trade-off between the effectiveness and safety of atypical antipsychotics in the treatment of BPSD and confirms that a single most effective and safe treatment option does not exist. Clinicians should individualize the assessment of safety risks against expected benefits when prescribing these medications to patients with dementia.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Yunusa I, Alsumali A, Garba AE, et al. Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia: A Network Meta-analysis. JAMA Netw Open. 2019. PMID: 30901041. doi:10.1001/jamanetworkopen.2019.0828

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。